NEWS

Back

Signing a Memorandum of Understanding on the prevention of coronavirus infection between The Gamaleya Research Institute, AstraZeneca and R-Pharm

Signing a Memorandum of Understanding on the prevention of coronavirus infection between The Gamaleya Research Institute, AstraZeneca and R-Pharm

 

Under the chairmanship of the Russian President Mr Vladimir Putin on December, 21 this year the Memorandum of Understanding on the prevention of coronavirus infection (COVID-19) was signed by the Gamaleya Research Institute of Epidemiology and Microbiology, the British-Swedish company "AstraZeneca", the Russian Direct Investment Fund and the company "R-Pharm".

In particular, the Parties agreed on the development and implementation of one of the components of the Russian vaccine "Sputnik V" made by the Gamaleya Research Institute, and one of the components of the AZD1222 vaccine, developed by AstraZeneca in conjunction with the University of Oxford in order to achieve more persistent and long-term immunization of an individual against coronavirus infection.

Clinical study of the AZD1222 vaccine combination with the adenoviral vector of the "Sputnik V" vaccine will begin shortly. The Russian company "R-Pharm" will also co-sponsor the study.

The uniqueness of the Russian vaccine is in the use of two different vectors based on the human adenovirus, which allows to achieve stronger and longer-term immune response compared to vaccines using the same vector for two injections.

More detailed information on the analysis of clinical trials can be found via the link: https://rdif.ru/fullNews/6057/.

Additional information on signing the memorandum can be found via the following link: http://kremlin.ru/events/president/news/64683.